Pharmaceuticals Industry Report

Tuesday, May 15, 2018

Worldwide Cytomegalovirus Retinitis Market Size, Share, Development, Growth and Demand Forecast to 2023

One of the major trends noticed in the cytomegalovirus retinitis market is usage of off-label drugs for the treatment of cytomegalovirus retinitis. Innovation of products focusing on better efficacy, growing demographics and growing economies in the developing countries, such as China and India, are some of the opportunities for global cytomegalovirus retinitis market.

Request for Sample Copy of this Research Report At: https://bit.ly/2wHbuSv

Cytomegalovirus retinitis is eye disease caused due to retina inflammation of eye. The causative agent of the disease is cytomegalovirus, a herpes virus that affects the photosensitive cells of retina. After affecting the retina, the disease spreads from one eye to another eye, which can lead to blindness, if left untreated. Photophobia, blurred vision, seeing floaters and blind spots are the symptoms of cytomegalovirus retinitis.

Some of the major factors restraining the growth of the global cytomegalovirus retinitis market are lack of awareness among people for different types of eye diseases, rising healthcare cost in developing countries and lack of healthcare insurance.

North America has the largest market for cytomegalovirus retinitis due to improved medical facilities and increasing occurrence of cytomegalovirus retinitis cases in the region. Asia-Pacific is growing with the highest rate among global cytomegalovirus retinitis market.

In Asia-Pacific, China and India are the two fastest growing cytomegalovirus retinitis markets, attributed to raising government initiatives and support and large population in these countries.

Some of the major competitors of global cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.

Explore Report At: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market

Thursday, May 10, 2018

Global Benign Prostatic Hyperplasia (BPH) Procedures - Expected High Demand for BPH treatments by 2023

Increase in the aging population in the U.S in the next few years, is expected to create high demand for Benign Prostatic Hyperplasia (BPH) treatments, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, TUIP and laser based treatments.

Here, you can download sample of this research report - Please visit: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

According to the National Institute of Health, it has been estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than 80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH procedures.

The advanced research and development activities has led to the development of technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and targeted sterile water vapor therapy (Rezum) are some of the recent technological therapies launched for BPH management. Rezum is a minimally invasive procedure that uses steam in the treatment of enlarged prostate and is currently available in the U.S. These therapies can be performed in a clinic or at an outpatient facility, and thereby reduce the cost associated with hospital stay and surgeries.

As per the findings of the research, the different type of BPH treatment procedure include laser based procedures, surgical procedures, UroLift and other energy based procedures. Laser based procedures is expected to account for the largest share in the U.S. BPH procedures during the forecast period, since these procedures are more effective, as compared to the conventional procedures and are less likely to cause bleeding and other complications.

Some of the key players providing products for BPH procedures in the U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Global Industry Insight: Human Insulin Market Development and Demand Forecast to 2020

The global human insulin market was valued at $23,981.6 million in 2014. The market is expected to grow at a CAGR of 12.5% during the period 2015 to 2020, to reach $48,487.7 million value by 2020. The global human insulin market is being driven by increasing prevalence of diabetic population, and rise in aging population. Diabetes is a chronic and non-communicable disease, and its global prevalence is increasing enormously. Rising prevalence of obesity, rising awareness about diabetic care, and technological advancement in insulin delivery devices are some of the factors driving the growth of the global human insulin market.

Request for Sample of this Research Report, Please Visit: https://www.psmarketresearch.com/market-analysis/human-insulin-market/report-sample

On the basis of type of human insulin, the modern human insulin commands the larger share in the global market. The modern human insulin is also expected to grow at a CAGR (of 13%) than traditional human insulin during 2015 to 2020. The modern human insulin can be further categorized as long acting human insulin, rapid acting human insulin and premixed human insulin; wherein, the long acting human insulin commands the largest share in modern human insulin market but the premixed human insulin exhibited the highest growth rate.

Increasing prevalence of diabetes, increasing number of geriatric population, rising prevalence of obesity and increasing R&D investment for more effective insulin are driving the growth of the human insulin market in North America. The North American human insulin market is expected to grow by a CAGR of 11.8% during the period 2015 to 2020.

The global human insulin market has a fragmented structure with large number of companies operating in the market. The key players in the human insulin market include Sanofi, Novo Nordisk A/S, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer, Inc., Merck & Co., and Julphar.